Expansion and enhancement of services for medical institutions
First written in FY2020. 10 of 21 entries say "Advanced", first in FY2021-Q1. Latest entry: 2026-08-05.
1 other company's latest entry also says "Advanced".
- 2026-08-05AdvancedResults presentation
「The business serving healthcare providers continues to expand, supported by steady demand from medical institutions and clinics. 4,571 +20%」
The business serving healthcare providers recorded quarterly revenue of ¥4,571 million, representing 20% year-on-year growth and continued expansion. - FY2026AdvancedAnnual report
「The Company has continued to expand its business through drug databases, consulting services to improve the management and operations of medical institutions using data, and factoring of medical reimbursement receivables. Revenue from the business for the fiscal year under review was ¥17,203 million, up 29.5% from ¥13,284 million in the previous fiscal year.」
Revenue from the healthcare-provider business, including drug databases, consulting for medical institutions and factoring of medical reimbursement receivables, increased 29.5% to ¥17,203 million. - FY2026-H1RestatedAnnual report
「We also provide medical data analysis services, medical reimbursement factoring services, and drug databases to medical institutions.」
The disclosure reconfirms the provision of services to medical institutions, including medical data analytics, medical reimbursement factoring and drug databases. - FY2025AdvancedAnnual report
「The Company has continued to expand its business through drug databases, consulting services to improve the management and operations of medical institutions using data, and factoring of medical reimbursement receivables. Revenue from the business for the fiscal year under review was ¥13,284 million, up 46.1% from ¥9,095 million in the previous fiscal year.」
Revenue from the healthcare-provider business increased 46.1% to ¥13,284 million. The disclosure describes expansion of the business, including drug databases, consulting to improve management and operations, and factoring of medical reimbursement receivables. - FY2024AdvancedAnnual report
「The Company has continued to expand its business through drug databases, consulting services to improve the management and operations of medical institutions using data, and factoring of medical reimbursement receivables. Revenue from the business for the fiscal year under review was ¥9,095 million, up 36.0% from ¥6,689 million in the previous fiscal year.」
Revenue from the healthcare-provider business increased 36.0% to ¥9,095 million. The disclosure describes the expansion of drug databases, consulting for medical institutions and factoring of medical reimbursement receivables. - FY2024-Q3RestatedAnnual report
「We also provide medical data analysis services, medical reimbursement factoring services, and drug databases to medical institutions.」
The disclosure reconfirms the provision of services to medical institutions, including medical data analytics, medical reimbursement factoring and drug databases. - FY2024-Q2RestatedAnnual report
「We also provide medical data analysis services, medical reimbursement factoring services, and drug databases to medical institutions.」
The disclosure reconfirms the provision of services to medical institutions, including medical data analytics, medical reimbursement factoring and drug databases. - FY2024-Q1RestatedAnnual report
「We also provide medical data analysis services, medical reimbursement factoring services, and drug databases to medical institutions.」
The disclosure reconfirms the provision of services to medical institutions, including medical data analytics, medical reimbursement factoring and drug databases. - FY2023AdvancedAnnual report
「The Company has continued to expand its business through drug databases, consulting services to improve the management and operations of medical institutions using data, and factoring of medical reimbursement receivables. Revenue from the business for the fiscal year under review was ¥6,689 million, up 47.0% from ¥4,551 million in the previous fiscal year.」
Revenue from the healthcare-provider business, including drug databases, consulting for medical institutions and factoring of medical reimbursement receivables, increased 47.0% to ¥6,689 million. - FY2023-Q3RestatedAnnual report
「We also provide medical data analysis services, medical reimbursement factoring services, and drug databases to medical institutions.」
The disclosure reconfirms the provision of services to medical institutions, including medical data analytics, medical reimbursement factoring and drug databases. - FY2023-Q2RestatedAnnual report
「We also provide medical data analysis services, medical reimbursement factoring services, and drug databases to medical institutions.」
The disclosure reconfirms the provision of services to medical institutions, including medical data analytics, medical reimbursement factoring and drug databases. - FY2023-Q1RestatedAnnual report
「We also provide medical data analysis services, medical reimbursement factoring services, and drug databases to medical institutions.」
The disclosure reconfirms the provision of services to medical institutions, including medical data analytics, medical reimbursement factoring and drug databases. - FY2022AdvancedAnnual report
「The Company has continued to expand its business through drug databases, consulting services to improve the management and operations of medical institutions using data, and factoring of medical reimbursement receivables. Revenue from the business for the fiscal year under review was ¥4,551 million, up 36.3% from ¥3,340 million in the previous fiscal year.」
Revenue from the healthcare-provider business, including drug databases, consulting for medical institutions and factoring of medical reimbursement receivables, increased 36.3% to ¥4,551 million. - FY2022-Q3AdvancedAnnual report
「The healthcare-provider business has continued to expand, driven by growth in downloads of the Ishiyaku medication app for physicians and the addition of 株式会社アイシーエム to the Group.」
The expansion of the physician medication app and the addition of 株式会社アイシーエム to the Group are identified as drivers of growth in the healthcare-provider business. - FY2022-Q2AdvancedAnnual report
「The business serving healthcare providers has also continued to expand through the launch of the Ishiyaku medication app for physicians and the addition of 株式会社アイシーエム to the Group.」
The launch of the Ishiyaku medication app for physicians and the addition of 株式会社アイシーエム to the Group are newly identified as drivers of expansion in the healthcare-provider business. - FY2022-Q1RestatedAnnual report
「We also provide medical data analysis services, medical reimbursement factoring services, and drug databases to medical institutions.」
The disclosure reconfirms the provision of services to medical institutions, including medical data analytics, medical reimbursement factoring and drug databases. - FY2021-Q3RestatedAnnual report
「In addition, revenue from the businesses serving insurers and consumers and those serving medical institutions also grew significantly.」
The disclosure reiterates that revenue from the businesses serving insurers and consumers and those serving medical institutions grew significantly. - FY2021-Q1AdvancedAnnual report
「Revenue from the businesses serving insurers, consumers, and medical institutions also grew substantially.」
The Company reported substantial growth in revenue, including from the business serving medical institutions. - FY2020First statedAnnual report
「In this business, we are focusing on expanding and enhancing services for medical institutions. The business is expanding steadily, led by the drug database business.」
The Company recorded as a new theme its policy of expanding services for medical institutions, including the drug database, medical institution data analytics, and management improvement consulting.